Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Monday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock, up from their previous target price of $6.00.

A number of other brokerages also recently issued reports on TSHA. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Thursday. Chardan Capital boosted their target price on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, May 16th. Finally, JMP Securities boosted their price objective on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a “market outperform” rating in a report on Thursday, May 29th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $7.29.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $2.79 on Monday. The stock’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $1.90. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a market cap of $598.91 million, a PE ratio of 4.43 and a beta of 0.90.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. During the same quarter last year, the business posted ($0.10) EPS. As a group, research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Granahan Investment Management LLC boosted its stake in shares of Taysha Gene Therapies by 0.3% in the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock worth $2,281,000 after buying an additional 4,412 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after buying an additional 8,076 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Taysha Gene Therapies by 43.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock worth $55,000 after buying an additional 9,494 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after buying an additional 9,591 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Taysha Gene Therapies by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after buying an additional 11,390 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.